Vir Biotechnology’s stock is largely controlled by a few key shareholders, with six entities owning 53%. Institutional investors have a powerful influence, both supporting Vir’s
Vir Biotechnology’s stock is largely controlled by a few key shareholders, with six entities owning 53%. Institutional investors have a powerful influence, both supporting Vir’s